Answer
Hypersensitivity reactions to Tysabri (natalizumab) usually occur during infusion or within 1 hour after completion, with greatest risk during early infusions or re-exposure after one or two infusions followed by at least three months without treatment, although risk exists with every infusion.
Sources for this answer
- TYSABRI 300 mg concentrate for solution for infusionBiogen Idec Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 43Document updated
Sources checked